Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 517-521, December 2009

Is there a role for maintenance therapy in acute myeloid leukaemia?

  • Maria R. Baer, MD (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +1 410 328 8708; Fax: +1 410 328 6896.

Greenebaum Cancer Center and Department of Medicine, University of Maryland School of Medicine, 22 South Greene St, Room S9D08, Baltimore, MD 21201, USA

Maintenance therapy is not part of current standard treatment for acute myeloid leukaemia (AML). However, in other leukaemias, maintenance therapy is used to prolong responses and increase the cure rate. While maintenance chemotherapy has not been shown to improve outcome in AML, several other maintenance strategies are currently being tested in this disease, including immunotherapy, demethylating agents and targeted therapies. While maintenance chemotherapy does not appear to have a role in AML curative therapy, the novel maintenance strategies currently being tested appear promising and warrant further study.

Keywords: acute myeloid leukaemia, maintenance, immunotherapy, demethylating agents, interleukin–2, histamine, vaccines, tipifarnib, lestaurtinib, midostaurin, FLT3

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(09)00064-4

doi:10.1016/j.beha.2009.09.001

Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 517-521, December 2009

Article Tools